Sorry, you need to enable JavaScript to visit this website.

SOMAVERT® (pegvisomant) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SOMAVERT safely and effectively. See full prescribing information for SOMAVERT.

SOMAVERT (pegvisomant) for injection, for subcutaneous use
Initial U.S. Approval: 2003

INDICATIONS AND USAGE

SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.(1)

DOSAGE AND ADMINISTRATION

  • Administer a 40 mg loading dose subcutaneously under physician supervision (2.1)
  • After proper injection instruction, on day after loading dose, patients or caregivers begin daily subcutaneous injections of 10 mg (2.1)
  • Adjust dosage in 5 mg increments or decrements until serum IGF-I concentrations are maintained within age-adjusted normal range. Do not adjust dosage based on growth hormone (GH) levels or signs or symptoms of acromegaly (2.1)
  • Dosage range is 10 to 30 mg once daily (2.1)
  • Perform liver tests prior to first dosage and if greater than 3 time upper limit of normal should work-up prior to SOMAVERT administration (2.2)
  • Follow reconstitution and injection procedures (2.3, 2.4)

DOSAGE FORMS AND STRENGTHS

For injection: 10, 15, 20, 25 or 30 mg (as protein) lyophilized powder in single-use vial for reconstitution (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

  • Hypoglycemia: Monitor blood glucose in patients with diabetes mellitus and reduce anti-diabetic drug therapy as necessary (5.1)
  • Liver Test Elevations: Should have more frequent liver tests and/or discontinue SOMAVERT (5.2)
  • Systemic Hypersensitivity: Monitor closely when re-initiating SOMAVERT in patients with systemic hypersensitivity (5.5)

ADVERSE REACTIONS

Most common reported adverse reactions (> 6%) are infection, pain, nausea, diarrhea, abnormal liver tests, flu syndrome, injection site reaction (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (phone 1-800-438-1985 andwww.pfizer.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Insulin and/or Oral hypoglycemic Agents: Patients with acromegaly and with diabetes mellitus may require careful monitoring and dose reductions of insulin and/or oral hypoglycemic agents. (5.2, 7.1)
  • Opioids: Patients on opioids may need higher SOMAVERT doses to achieve appropriate IGF-I suppression. (7.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 4/2016

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Meet Our Team

Search

Please enter your search term(s) for SOMAVERT®

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.